ASH: No­var­tis rolls out ear­ly da­ta for a pair of 'sec­ond-gen' CAR-Ts with more pro­duc­tive cells de­liv­ered faster

The cur­rent gen­er­a­tion of cell ther­a­pies has proven a game chang­er in terms of treat­ing ag­gres­sive blood can­cers, but the tech has its lim­i­ta­tions. No­var­tis, one of the big­gies in the cur­rent gen­er­a­tion of these drugs, is now tak­ing lessons learned from CAR-T Kym­ri­ah to su­per­charge a “sec­ond-gen­er­a­tion” of CAR-Ts putting su­pe­ri­or cells in­to pa­tients faster.

No­var­tis on Mon­day rolled out ear­ly Phase I da­ta for a pair of au­tol­o­gous CAR-T cell ther­a­pies de­vel­oped through the drug­mak­er’s T-Charge plat­form, a process de­signed to pro­mote T cell “stem­ness” — a mea­sure of a cell’s abil­i­ty to self-re­new — by cut­ting man­u­fac­tur­ing times and spurring cell pro­lif­er­a­tion pri­mar­i­ly in pa­tients’ lymph nodes.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN